300199 翰宇药业
已收盘 10-23 15:00:00
资讯
新帖
简况
翰宇药业：公司及武汉原料药生产基地均已通过美国 FDA cGMP 现场检查
证券之星 · 10-21 20:51
翰宇药业：公司及武汉原料药生产基地均已通过美国 FDA cGMP 现场检查
翰宇药业：已建立包括高级结构表征在内的系统化研究平台
证券之星 · 10-20 20:52
翰宇药业：已建立包括高级结构表征在内的系统化研究平台
翰宇药业：公司在 AI 制药方向采取 "合作引进、分步落地" 的思路
证券之星 · 10-20 20:52
翰宇药业：公司在 AI 制药方向采取 "合作引进、分步落地" 的思路
翰宇药业：HY3003周制剂注射液国内临床试验申请已获受理
证券之星 · 10-20 20:52
翰宇药业：HY3003周制剂注射液国内临床试验申请已获受理
翰宇药业：公司替尔泊肽两项ANDA已向FDA递交并提交四段专利挑战声明
证券之星 · 10-20 20:52
翰宇药业：公司替尔泊肽两项ANDA已向FDA递交并提交四段专利挑战声明
翰宇药业：公司在复杂多肽药物领域已形成从原料药到制剂的一体化布局
证券之星 · 10-20 20:51
翰宇药业：公司在复杂多肽药物领域已形成从原料药到制剂的一体化布局
翰宇药业（300199）10月19日主力资金净买入1.59亿元
证券之星 · 10-20
翰宇药业（300199）10月19日主力资金净买入1.59亿元
翰宇药业（300199）披露2026年前三季度业绩预告，10月13日股价上涨2.65%
证券之星 · 10-13
翰宇药业（300199）披露2026年前三季度业绩预告，10月13日股价上涨2.65%
翰宇药业前三季度净利预增逾5倍 HY3003获美国FDA临床受理
东方财富网 · 10-13
翰宇药业前三季度净利预增逾5倍 HY3003获美国FDA临床受理
翰宇药业：预计2026年1-9月扣非后净利润盈利4.2亿元至4.4亿元
证券之星 · 10-12
翰宇药业：预计2026年1-9月扣非后净利润盈利4.2亿元至4.4亿元
翰宇药业：预计2026年1-9月归属净利润盈利4.3亿元至4.5亿元
证券之星 · 10-12
翰宇药业：预计2026年1-9月归属净利润盈利4.3亿元至4.5亿元
翰宇药业：预计2026年前三季度净利同比增503%-531%
格隆汇 · 10-12
翰宇药业：预计2026年前三季度净利同比增503%-531%
翰宇药业最新公告：预计2026年前三季度净利润同比增长503%-531%
证券之星 · 10-12
翰宇药业最新公告：预计2026年前三季度净利润同比增长503%-531%
翰宇药业（300199）披露HY3003注射液获美国FDA临床试验申请受理，10月9日股价下跌0.17%
证券之星 · 10-09
翰宇药业（300199）披露HY3003注射液获美国FDA临床试验申请受理，10月9日股价下跌0.17%
翰宇药业(300199.SZ)：HY3003注射液获得美国FDA临床试验申请受理
智通财经 · 10-08
翰宇药业(300199.SZ)：HY3003注射液获得美国FDA临床试验申请受理
翰宇药业（300199）9月24日主力资金净卖出1411.57万元
证券之星 · 09-28
翰宇药业（300199）9月24日主力资金净卖出1411.57万元
翰宇药业(300199.SZ)：HY3003注射液临床试验申请获受理
智通财经 · 09-10
翰宇药业(300199.SZ)：HY3003注射液临床试验申请获受理
翰宇药业（300199）披露全资子公司卡前列素氨丁三醇注射液获得药品注册证书，9月8日股价下跌2.35%
证券之星 · 09-08
翰宇药业（300199）披露全资子公司卡前列素氨丁三醇注射液获得药品注册证书，9月8日股价下跌2.35%
翰宇药业(300199.SZ)：卡前列素氨丁三醇注射液获得药品注册证书
智通财经 · 09-07
翰宇药业(300199.SZ)：卡前列素氨丁三醇注射液获得药品注册证书
翰宇药业：多肽原料药产能计划本年度内达到10吨级
证券之星 · 09-02
翰宇药业：多肽原料药产能计划本年度内达到10吨级
加载更多
公司概况
公司名称：
深圳翰宇药业股份有限公司
所属行业：
医药制造业
上市日期：
2011-04-07
主营业务：
深圳翰宇药业股份有限公司的主营业务是多肽制剂、原料药、小核酸与CRDMO的研发、销售。公司的主要产品是多肽制剂、原料药、小核酸与CRDMO。公司共获得国内专利四百余项，国际专利数十项，各类多肽药物批件、新药证书和临床批件，配备国际领先的研发实验室及300余台（套）高端设备（如全自动合成系统、大容量纯化系统等），为国内领先。
发行价格：
30.19
{"stockData":{"symbol":"300199","market":"SZ","secType":"STK","nameCN":"翰宇药业","latestPrice":25.8,"timestamp":1792739013000,"preClose":24.64,"halted":0,"volume":56935914,"delay":0,"changeRate":0.0471,"floatShares":745000000,"shares":883000000,"eps":0.1447,"marketStatus":"已收盘","change":1.16,"latestTime":"10-23 15:00:00","open":24.34,"high":25.96,"low":24.02,"amount":1422000000,"amplitude":0.0787,"askPrice":25.8,"askSize":362,"bidPrice":25.79,"bidSize":128,"shortable":0,"etf":0,"ttmEps":0.1447,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":5,"adr":0,"adjPreClose":24.64,"symbolType":"stock","openAndCloseTimeList":[[1792719000000,1792726200000],[1792731600000,1792738800000]],"highLimit":27.1,"lowLimit":22.18,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":883241336,"isCdr":false,"pbRate":25.6,"roa":"--","peRate":178.299931,"roe":"32.33%","epsLYR":0.04,"committee":0.608984,"marketValue":22788000000,"turnoverRate":0.0765,"status":0,"floatMarketCap":19214000000},"requestUrl":"/m/hq/s/300199","defaultTab":"news","newsList":[{"id":"2677717676","title":"翰宇药业：公司及武汉原料药生产基地均已通过美国 FDA cGMP 现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2677717676","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677717676?lang=zh_cn&edition=full","pubTime":"2026-10-21 20:51","pubTimestamp":1792587067,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业(300199)10月20日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司（含武汉原料药基地）是否已被列入 FDA Import Alert 66-80 的 Green List？公司司美格鲁肽/替尔泊肽原料药对美出口是否受该进口警示影响？翰宇药业回复：尊敬的投资者，您好！公司及武汉原料药生产基地均已通过美国 FDA cGMP 现场检查，其中武汉原料药基地以 NAI（零缺陷）结论通过核查。公司将持续严格按照美国cGMP要求组织生产与出口，依法合规推进全球化布局。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100039156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0070","300199","BK0028","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676835696","title":"翰宇药业：已建立包括高级结构表征在内的系统化研究平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2676835696","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676835696?lang=zh_cn&edition=full","pubTime":"2026-10-20 20:52","pubTimestamp":1792500731,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业10月20日在投资者关系平台上答复投资者关心的问题。公司在多肽质量研究方面已建立包括高级结构表征在内的系统化研究平台，可完成活性成分一致性、高级结构确证、杂质分析、稳定性评价等注册所需的体外表证工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000034465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK0188","BK0028","300199","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676696859","title":"翰宇药业：公司在 AI 制药方向采取 \"合作引进、分步落地\" 的思路","url":"https://stock-news.laohu8.com/highlight/detail?id=2676696859","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676696859?lang=zh_cn&edition=full","pubTime":"2026-10-20 20:52","pubTimestamp":1792500731,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业(300199)10月20日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在AI制药领域有何前瞻性布局？翰宇药业回复：尊敬的投资者，您好！公司在 AI 制药方向采取 \"合作引进、分步落地\" 的思路，依托与碳云智肽的战略合作及战略参股；并结合多肽芯片、分子大模型和各类先进大模型开展创新分子的设计筛选，逐步搭建 \"AI + 多肽\" 研发平台。具体进展以公司正式公告为准，感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000034466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","300199","BK0239","BK1574","01477","BK0028","BK0070","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676968436","title":"翰宇药业：HY3003周制剂注射液国内临床试验申请已获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2676968436","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676968436?lang=zh_cn&edition=full","pubTime":"2026-10-20 20:52","pubTimestamp":1792500730,"startTime":"0","endTime":"0","summary":"能否介绍HY3003当前临床推进状态、差异化设计亮点，以及长期管线价值？HY3003系一款利用AI多肽芯片技术筛选出的GLP-1R/GIPR/GCGR三靶点受体激动剂，拟用于减重、2型糖尿病、代谢相关脂肪性肝炎等适应症，是公司在代谢疾病领域布局的重磅创新药品种。目前周制剂注射液国内临床试验申请已获受理，美国 FDA 临床试验申请亦于近期获得受理。HY3003的后续进展及相关数据均以公司正式公告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000034464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300199","BK0077","BK0188","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676696812","title":"翰宇药业：公司替尔泊肽两项ANDA已向FDA递交并提交四段专利挑战声明","url":"https://stock-news.laohu8.com/highlight/detail?id=2676696812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676696812?lang=zh_cn&edition=full","pubTime":"2026-10-20 20:52","pubTimestamp":1792500730,"startTime":"0","endTime":"0","summary":"投资者提问：公司替尔泊肽两项ANDA于5月13日同步递交FDA并提交 Paragraph IV四段专利挑战，礼来是否在45天窗口期内发起诉讼？请介绍该事件对公司ANDA审评进程带来的积极影响，以及后续FDA审评、现场核查的准备情况？公司替尔泊肽两项ANDA已向FDA递交并提交四段专利挑战声明，目前处于受理审查阶段。公司将按FDA要求配合推进审评并做好相应准备，后续进展均以公司正式公告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000034461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0070","300199","BK0028","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676968176","title":"翰宇药业：公司在复杂多肽药物领域已形成从原料药到制剂的一体化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2676968176","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676968176?lang=zh_cn&edition=full","pubTime":"2026-10-20 20:51","pubTimestamp":1792500719,"startTime":"0","endTime":"0","summary":"公司在复杂多肽药物领域已形成从原料药到制剂的一体化布局，在长链多肽的合成纯化，杂质的分析与管控、以及药物结构的研究确证、规模化放大、注册申报等方面积累了相应的自主技术能力，并通过高端制剂与包装的配套开发，保障产品从研发到商业化的稳定落地；利拉鲁肽、醋酸格拉替雷两款注射剂先后在美国获批并实现商业化，即是这一整体能力的体现，具体技术细节以公司公开披露为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000034458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0070","BK0239","300199","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676763067","title":"翰宇药业（300199）10月19日主力资金净买入1.59亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676763067","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676763067?lang=zh_cn&edition=full","pubTime":"2026-10-20 09:04","pubTimestamp":1792458273,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月19日收盘，翰宇药业报收于26.3元，上涨5.5%，换手率10.61%，成交量78.98万手，成交额20.17亿元。近5日资金流向一览见下表：翰宇药业融资融券信息显示，融资方面，当日融资买入1.8亿元，融资偿还1.46亿元，融资净买入3422.24万元。翰宇药业主营业务：核心业务聚焦四大板块:多肽制剂、原料药、小核酸与CRDMO。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000006147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0028","BK0239","BK0070","BK0188","300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675433703","title":"翰宇药业（300199）披露2026年前三季度业绩预告，10月13日股价上涨2.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675433703","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675433703?lang=zh_cn&edition=full","pubTime":"2026-10-13 17:33","pubTimestamp":1791884002,"startTime":"0","endTime":"0","summary":"截至2026年10月13日收盘，翰宇药业报收于25.55元，较前一交易日上涨2.65%，最新总市值为225.67亿元。该股当日开盘25.18元，最高26.38元，最低24.98元，成交额达26.72亿元，换手率为13.96%。公司于2026年10月13日披露《2026年前三季度业绩预告》。本次业绩预告未经会计师事务所审计，具体财务数据将在2026年三季度报告中披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300029275.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0028","BK0239","BK0077","BK0188","300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675880195","title":"翰宇药业前三季度净利预增逾5倍 HY3003获美国FDA临床受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2675880195","media":"东方财富网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675880195?lang=zh_cn&edition=full","pubTime":"2026-10-13 00:01","pubTimestamp":1791820868,"startTime":"0","endTime":"0","summary":"10月12日晚间，翰宇药业(300199)披露2026年前三季度业绩预告。2026年1月至9月，公司经营业绩同比大幅上升，营收与净利润双双实现高速增长，同时核心创新管线同步取得突破，长期成长动能持续释放。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://finance.eastmoney.com/news/1354,202610133893035354.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202610133893035354.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["300199","LABU","BK4585","BK0028","BK0077","BK0239","BK4588","BK0188","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674776038","title":"翰宇药业：预计2026年1-9月扣非后净利润盈利4.2亿元至4.4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674776038","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674776038?lang=zh_cn&edition=full","pubTime":"2026-10-12 20:00","pubTimestamp":1791806434,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业发布业绩预告，预计2026年1-9月扣非后净利润盈利4.2亿元至4.4亿元。翰宇药业2026年中报显示，上半年度公司主营收入6.88亿元，同比上升25.27%；归母净利润2.37亿元，同比上升62.72%；扣非净利润2.29亿元，同比上升85.9%；其中2026年第二季度，公司单季度主营收入3.89亿元，同比上升62.5%；单季度归母净利润1.09亿元，同比上升44.03%；单季度扣非净利润1.06亿元，同比上升82.5%；负债率75.65%，投资收益6539.83万元，财务费用5019.09万元，毛利率62.91%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200030979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674606877","title":"翰宇药业：预计2026年1-9月归属净利润盈利4.3亿元至4.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674606877","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674606877?lang=zh_cn&edition=full","pubTime":"2026-10-12 20:00","pubTimestamp":1791806434,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业发布业绩预告，预计2026年1-9月归属净利润盈利4.3亿元至4.5亿元。翰宇药业2026年中报显示，上半年度公司主营收入6.88亿元，同比上升25.27%；归母净利润2.37亿元，同比上升62.72%；扣非净利润2.29亿元，同比上升85.9%；其中2026年第二季度，公司单季度主营收入3.89亿元，同比上升62.5%；单季度归母净利润1.09亿元，同比上升44.03%；单季度扣非净利润1.06亿元，同比上升82.5%；负债率75.65%，投资收益6539.83万元，财务费用5019.09万元，毛利率62.91%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200030982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674874337","title":"翰宇药业：预计2026年前三季度净利同比增503%-531%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674874337","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674874337?lang=zh_cn&edition=full","pubTime":"2026-10-12 19:01","pubTimestamp":1791802860,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","BK0070","300199","BK0028","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674887459","title":"翰宇药业最新公告：预计2026年前三季度净利润同比增长503%-531%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674887459","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674887459?lang=zh_cn&edition=full","pubTime":"2026-10-12 18:59","pubTimestamp":1791802797,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，预计2026年前三季度归属于上市公司股东的净利润为4.30亿元-4.50亿元，同比增长502.65%-530.68%。报告期内公司原料药业务持续放量，带来营收、利润双增长。同时公司在三靶点创新药HY3003、小核酸等项目研发投入同比大幅增加。注：公司Q3净利润预计1.93亿-2.13亿，Q2净利润1.09亿，据此计算，Q3净利润预计环比增长77%-95%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200028153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674830933","title":"翰宇药业（300199）披露HY3003注射液获美国FDA临床试验申请受理，10月9日股价下跌0.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674830933","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674830933?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:30","pubTimestamp":1791538248,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，翰宇药业报收于23.71元，较前一交易日下跌0.17%，最新总市值为209.42亿元。该股当日开盘23.52元，最高23.84元，最低22.74元，成交额达9.69亿元，换手率为5.58%。公司于近日披露《关于HY3003注射液获得美国FDA临床试验申请受理的公告》。本次申请的适应症为成人长期体重管理，临床前研究显示其在减重、降糖、减脂及改善肝脏脂肪变性方面表现良好。公司将在FDA审查期结束后视情况启动人体临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900027136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0188","BK0028","BK0077","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673402225","title":"翰宇药业(300199.SZ)：HY3003注射液获得美国FDA临床试验申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2673402225","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673402225?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:30","pubTimestamp":1791448240,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布公告，公司于近日收到美国食品药品监督管理局(FDA)下发的关于HY3003注射液的临床试验申请受理通知。HY3003系一款利用AI多肽芯片技术筛选出的GLP-1R/GIPR/GCGR三靶点受体激动剂，拟用于减重、2型糖尿病、代谢相关脂肪性肝炎等适应症，是公司在代谢疾病领域布局的重磅创新药品种。HY3003项目采用多剂型并行的开发策略，开发方向包括HY3003注射液(周制剂)、HY3003缓释注射液(月制剂)以及 HY3003片(每日一次的口服制剂)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BBC","BK0239","300199","BK0028","BK0077","BK0070","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670077894","title":"翰宇药业（300199）9月24日主力资金净卖出1411.57万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670077894","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670077894?lang=zh_cn&edition=full","pubTime":"2026-09-28 09:25","pubTimestamp":1790558726,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月24日收盘，翰宇药业报收于23.3元，下跌4.08%，换手率5.9%，成交量43.96万手，成交额10.43亿元。近5日资金流向一览见下表：翰宇药业融资融券信息显示，融资方面，当日融资买入1.11亿元，融资偿还8396.1万元，融资净买入2663.18万元。翰宇药业主营业务：核心业务聚焦四大板块:多肽制剂、原料药、小核酸与CRDMO。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800002962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0028","BK0188","BK0239","300199","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666566579","title":"翰宇药业(300199.SZ)：HY3003注射液临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666566579","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666566579?lang=zh_cn&edition=full","pubTime":"2026-09-10 16:21","pubTimestamp":1789028518,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业 发布公告，公司于近日收到国家药品监督管理局核准签发关于HY3003注射液临床试验申请的《受理通知书》。该项目通过人工智能结合多肽芯片技术筛选得到新型多肽分子，由翰宇药业负责临床前研究、IND申报及后续临床试验开发。HY3003拟用于减重、2型糖尿病、代谢相关脂肪性肝炎等适应症，是公司在代谢疾病领域布局的重磅创新药品种。HY3003项目是翰宇药业与碳云智肽在“AI+多肽”领域深度合作的典范。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","PSYK","300199","IBBJ","IBBQ","MDTX","BMED","BK0188","BK0028","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665132946","title":"翰宇药业（300199）披露全资子公司卡前列素氨丁三醇注射液获得药品注册证书，9月8日股价下跌2.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665132946","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665132946?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:53","pubTimestamp":1788861203,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，翰宇药业报收于22.88元，较前一交易日下跌2.35%，最新总市值为202.09亿元。该股当日开盘23.51元，最高23.58元，最低22.81元，成交额达7.75亿元，换手率为4.52%。翰宇药业当日发布公告称，公司全资子公司甘肃成纪生物药业有限公司近日收到国家药品监督管理局签发的卡前列素氨丁三醇注射液《药品注册证书》，药品注册分类为化学药品4类，视为通过仿制药质量和疗效一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800027822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","BK0239","BK0070","BK0188","300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665318933","title":"翰宇药业(300199.SZ)：卡前列素氨丁三醇注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2665318933","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665318933?lang=zh_cn&edition=full","pubTime":"2026-09-07 16:51","pubTimestamp":1788771112,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布公告，公司全资子公司甘肃成纪生物药业有限公司(以下简称“成纪药业”)于近日收到国家药品监督管理局签发的卡前列素氨丁三醇注射液《药品注册证书》。卡前列素氨丁三醇注射液为前列腺素类药物，主要用于治疗因宫缩乏力所致的产后出血，是临床常用的产后止血药物。本次卡前列素氨丁三醇注射液获得药品注册证书，丰富了公司及子公司成纪药业在妇产科领域的产品管线，有利于提升公司在妇科止血类药物市场的竞争力。公司将按照相关要求尽快推进该产品的上市销售工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492782.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰宇药业(300199.SZ)：卡前列素氨丁三醇注射液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK0028","BK0239","BK0070","BK0188","300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664681814","title":"翰宇药业：多肽原料药产能计划本年度内达到10吨级","url":"https://stock-news.laohu8.com/highlight/detail?id=2664681814","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664681814?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:51","pubTimestamp":1788353492,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业09月01日在投资者关系平台上答复投资者关心的问题。武汉的产能规划是否达成预期？按照券商研报显示,片剂的用量会是针剂原料药用量的50-90倍。关于公司多肽原料药产能正在按需扩产中，计划本年度内达到10吨级，同时根据公司战略发展规划结合GLP-1市场的蓬勃发展，预计在2027年扩产至20吨级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200040551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0070","BK0077","BK0239","BK0188","300199"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792742215838,"stockEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":0.0331},{"period":"3month","weight":0.2388},{"period":"6month","weight":0.1334},{"period":"1year","weight":0.1392},{"period":"ytd","weight":0.3765}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0744},{"period":"3month","weight":-0.0409},{"period":"6month","weight":-0.1034},{"period":"1year","weight":-0.0653},{"period":"ytd","weight":-0.0783}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳翰宇药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"67294人(较上一季度减少31.87%)","perCapita":"11066股","listingDate":"2011-04-07","address":"广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼","registeredCapital":"88324万元","survey":" 深圳翰宇药业股份有限公司的主营业务是多肽制剂、原料药、小核酸与CRDMO的研发、销售。公司的主要产品是多肽制剂、原料药、小核酸与CRDMO。公司共获得国内专利四百余项，国际专利数十项，各类多肽药物批件、新药证书和临床批件，配备国际领先的研发实验室及300余台（套）高端设备（如全自动合成系统、大容量纯化系统等），为国内领先。","listedPrice":30.19},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰宇药业,300199,翰宇药业股票,翰宇药业股票老虎,翰宇药业股票老虎国际,翰宇药业行情,翰宇药业股票行情,翰宇药业股价,翰宇药业股市,翰宇药业股票价格,翰宇药业股票交易,翰宇药业股票购买,翰宇药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}